Nov 07, 2024 / 01:30PM GMT
Ryan Rhodes - Edap Tms SA - Chief Executive Officer
Future sales as we are currently in discussions with multiple hospitals within the HCA group, we also continue to experience strong growth in US focal one HIFU procedures during the quarter US procedures grew 34% on a year over year basis, which reflects continued adoption by urologists who see focal one as an important treatment option for delivering targeted focal therapy in earlier stage prostate cancer patients.
As mentioned during our last call, we believe that as the results from the groundbreaking HIFI study become more widely disseminated demand for the focal one platform will continue to grow.
The Hi fi study presents clear and compelling evidence that robotic HIFU therapy delivered by EDAP's proprietary technology is as effective as radical prostatectomy as a frontline treatment for the management of localized prostate cancer. While additionally offering patients better functional outcomes with respect to preservation of urinary continence and sexual function.
As a reminder, EDAP technology was used exclusively to
Q3 2024 Edap Tms SA Earnings Call Transcript
Nov 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers